Skip to main content

Table 2 Effectiveness In Superiority Trials Assessed By Random Risk Ratio and Heterogeneity

From: Intensive therapy and remissions in rheumatoid arthritis: a systematic review

  Treatments Trials Comparisons Random Risk Ratio (95% CI) Heterogeneity
All All 48 52 2.23 (1.90, 2.61) I2 = 84%
DAS28 Remissions 38 40 2.26 (1.89, 2.71) I2 = 85%
Other Remission Criteria 10 12 2.13 (1.53, 2.98) I2 = 81%
6 Month Duration 21 24 3.78 (2.60, 5.51) I2 = 86%
12 Month Duration 19 20 1.73 (1.44, 2.09) I2 = 82%
18–36 Month Duration 8 8 1.84 (1.39, 2.42) I2 = 79%
Used TTT Strategy 8 9 1.62 (1.30, 2.03) I2 = 75%
Early Alla 22 23 1.56 (1.38, 1.76) I2 = 74%
TNF Inhibitors 13 13 1.44 (1.26, 1.66) I2 = 62%
Other Biologics 5 5 2.00 (1.53, 2.63) I2 = 79%
Combination DMARDSb 5 5 1.46 (1.11, 1.93) I2 = 73%
Used TTT Strategy 6 7 1.51 (1.22, 1.88) I2 = 72%
Established All 26 29 4.21 (2.92, 6.07) I2 = 86%
TNF Inhibitors 10 10 3.59 (2.14, 6.03) I2 = 70%
Other Biologics 10 10 6.81 (2.62, 17.7) I2 = 95%
Combination DMARDS 3 3 2.41 (1.14, 5.10) I2 = 67%
JAK Inhibitors 6 6 3.39 (2.14, 5.36) I2 = 0%
Used TTT Strategy 2 2 2.39 (0.90, 6.32) I2 = 83%
  1. aThe 4 very early trials which enrolled patients with disease durations no more than 6 months involved 4 comparisons with a random risk ratio (95% CI) of 1.47 (1.03, 2.10) and I2 72%
  2. bExcluding the Schipper et al. study in which some patients in both groups had DMARD monotherapy, DMARD combination therapy and TNF inhibitors leaves 4 trials with 4 comparisons with a random risk ratio (95% CI) of 1.38 (1.01, 1.88) and I2 71%
  3. Abbreviations: DAS28 Disease Activity Score for 28 joints, TNF Tumour necrosis factor, DMARDs Disease modifying anti-rheumatic drugs, JAK Janus kinase, TTT Treat To Target